Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Abstract: This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients.

Abstract: This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.

Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to determine metastasis-free survival of breast cancer patients. The biomarkers can be detected by SELDI mass spectrometry in serum samples fractionated by means of anion exchange chromatography. Some of the biomarkers have been identified as: Apolipoprotein A1; Apolipoprotein A2; Haptoglobin alpha 1; Transferrin; Complement C3a; and truncated forms thereof.

Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.

Abstract: The present invention relates to a method of qualifying pancreatic cancer status in a subject comprising: (a) measuring at least one of the disclosed biomarkers in a sample from the subject and (b) correlating the measurement with pancreatic cancer status. The invention further relates to kits for qualifying pancreatic cancer status in a subject.

Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Abstract: Processes for making neutral or anionic complexes containing sequestered DNA for gene transfer, by forming a stable colloid containing an aqueous phase having suspended therein a first DNA complex with a cationic surface potential comprising a DNA sequence complexed with a cationic lipid or polymer, and modifying the surface potential of the first DNA complex to form a stable colloid comprising a second DNA complex with a neutral or net anionic surface potential.

Abstract: Novel cationic polymers and cationic lipids, and methods of making and using the same, are provided. The cationic polymers and cationic lipids are useful for the delivery of nucleic acid polymers and oligomers to cells in vitro and in vivo.

Abstract: Novel cationic polymers and cationic lipids, and methods of making and using the same, are provided. The cationic polymers and cationic lipids are useful for the delivery of nucleic acid polymers and oligomers to cells in vitro and in vivo.